FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Elaine Chang, Yutao Gong, Chana Weinstock, Laura L Fernandes, Jessica Hawley, Thomas Gwise, Meredith M. Regan, Toni K. Choueiri, Brian I. Rini, David F. McDermott, Michael B. Atkins, Daniel L. Suzman, Amna Ibrahim, Shenghui Tang, Marc Robert Theoret, Paul Gustav Kluetz, Richard Pazdur, Julia A. Beaver
Institutions: United States Food and Drug Administration, Columbia University Irving Medical Center, Dana-Farber Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center, Cleveland Clinic, Beth Israel Deaconess Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Johns Hopkins University, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029923957